Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy

An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy

This study is an extended follow-up of the study (ClinicalTrials.gov ID: NCT01758120)-Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.

Inclusion Criteria:

• biopsy-proven primary IgA nephropathy
• 18-70 years old
• elevated serum Creatinine and less than 3.0mg/dl
• with a written consent from participants to receive prednisone and/or cyclophosphamide

Exclusion Criteria:

• diabetes;
• contraindications for the treatment of prednisone and/or cyclophosphamide
• any treatment with steroids or immunosuppressive drugs prior to this study
• acute deterioration of renal function(including those of glomerular origin)